321 related articles for article (PubMed ID: 10965415)
1. Effects of intravenous azimilide on cardiac performance, fibrillation threshold, and hemodynamics in anesthetized dogs.
Brooks RR; Finch SL
Arzneimittelforschung; 2000 Jul; 50(7):597-605. PubMed ID: 10965415
[TBL] [Abstract][Full Text] [Related]
2. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
Drexler AP; Micklas JM; Brooks RR
J Cardiovasc Pharmacol; 1996 Dec; 28(6):848-55. PubMed ID: 8961084
[TBL] [Abstract][Full Text] [Related]
3. Effects of azimilide, a KV(r) and KV(s) blocker, on canine ventricular arrhythmia models.
Xue Y; Yamada C; Chino D; Hashimoto K
Eur J Pharmacol; 1999 Jul; 376(1-2):27-35. PubMed ID: 10440086
[TBL] [Abstract][Full Text] [Related]
4. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs.
Wallace AA; Stupienski RF; Brookes LM; Selnick HG; Claremon DA; Lynch JJ
J Cardiovasc Pharmacol; 1991 Nov; 18(5):687-95. PubMed ID: 1723765
[TBL] [Abstract][Full Text] [Related]
5. Effects of azimilide dihydrochloride on circus movement atrial flutter in the canine sterile pericarditis model.
Restivo M; Hegazy M; Caref EB; Avitable MJ; Assadi MA; el-Hamami M; Yin H; Piracha M; Brooks RR; el-Sherif N
J Cardiovasc Electrophysiol; 1996 Jul; 7(7):612-24. PubMed ID: 8807407
[TBL] [Abstract][Full Text] [Related]
6. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation.
Qi XQ; Newman D; Dorian P
J Interv Card Electrophysiol; 1999 Mar; 3(1):61-7. PubMed ID: 10354978
[TBL] [Abstract][Full Text] [Related]
7. The class III effect of azimilide is not associated with reverse use-dependence in open-chest dogs.
Qi XQ; Newman D; Dorian P
J Cardiovasc Pharmacol; 1999 Dec; 34(6):898-903. PubMed ID: 10598136
[TBL] [Abstract][Full Text] [Related]
8. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation.
Pritchett EL; Schulte MC; Schnell D; Marcello SR; Wilkinson WE; Page RL; Connolly SJ;
J Clin Pharmacol; 2002 Apr; 42(4):388-94. PubMed ID: 11936563
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.
Knobloch K; Brendel J; Peukert S; Rosenstein B; Busch AE; Wirth KJ
Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):482-7. PubMed ID: 12382079
[TBL] [Abstract][Full Text] [Related]
10. Effects of azimilide and d,l-sotalol on the heart rate and blood pressure response to isoproterenol in anesthetized rats.
Mittelstadt SW; Maynard AE; Benn DR; Lowe ER; Kostreva DR
Cardiovasc Drugs Ther; 1997 Sep; 11(4):591-8. PubMed ID: 9358964
[TBL] [Abstract][Full Text] [Related]
11. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties.
Nattel S; Liu L; St-Georges D
Cardiovasc Res; 1998 Mar; 37(3):627-35. PubMed ID: 9659446
[TBL] [Abstract][Full Text] [Related]
12. The effect of isoproterenol on the class III effect of azimilide in humans.
Dorian P; Dunnmon P; Elstun L; Newman D
J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):211-7. PubMed ID: 12490966
[TBL] [Abstract][Full Text] [Related]
13. Effects of WAY-123,398, a new class III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs: a comparison with UK-68798, E-4031, and dl-sotalol.
Spinelli W; Parsons RW; Colatsky TJ
J Cardiovasc Pharmacol; 1992 Dec; 20(6):913-22. PubMed ID: 1282594
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia.
Brooks RR; Carpenter JF; Miller KE; Maynard AE
Proc Soc Exp Biol Med; 1996 May; 212(1):84-93. PubMed ID: 8618956
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall.
Yan GX; Wu Y; Liu T; Wang J; Marinchak RA; Kowey PR
Circulation; 2001 Jun; 103(23):2851-6. PubMed ID: 11401944
[TBL] [Abstract][Full Text] [Related]
16. Azimilide dihydrochloride, a novel antiarrhythmic agent.
Karam R; Marcello S; Brooks RR; Corey AE; Moore A
Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic effects of cibenzoline on normal myocardium and after pretreatment with DL-sotalol.
Beyer ME; Hoffmeister HM; Seipel L
J Cardiovasc Pharmacol; 1992 May; 19(5):657-64. PubMed ID: 1381761
[TBL] [Abstract][Full Text] [Related]
18. A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide.
Phillips L; Grasela TH; Agnew JR; Ludwig EA; Thompson GA
Clin Pharmacol Ther; 2001 Oct; 70(4):370-83. PubMed ID: 11673753
[TBL] [Abstract][Full Text] [Related]
19. Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit.
Brooks RR; Drexler AP; Maynard AE; Al-Khalidi H; Kostreva DR
Proc Soc Exp Biol Med; 2000 Feb; 223(2):183-9. PubMed ID: 10654622
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of isoproterenol-induced tachycardia by azimilide in the isolated perfused guinea pig heart.
Miller KE; Carpenter JF; Brooks RR
Cardiovasc Drugs Ther; 1998 Mar; 12(1):83-91. PubMed ID: 9607136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
